Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaccine therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    366 result(s) found for: Vaccine therapy. Displaying page 8 of 19.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2019-001565-33 Sponsor Protocol Number: RA101495-02.302 Start Date*: 2020-04-24
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028415 Myasthenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006260-52 Sponsor Protocol Number: THV01-11-01 Start Date*: 2012-10-12
    Sponsor Name:THERAVECTYS
    Full Title: A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or ...
    Medical condition: Human Immunodeficiency Virus type 1 infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004510-28 Sponsor Protocol Number: IM-201 Start Date*: 2015-03-05
    Sponsor Name:Immunicum AB
    Full Title: An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp...
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) LV (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006212-30 Sponsor Protocol Number: IMIRC1002 Start Date*: 2007-08-09
    Sponsor Name:Imperial College London
    Full Title: A Randomised, Open labelled, Phase II, Immunogenicity, and Exploratory Efficacy Evaluation of Therapeutic Immunisations +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving High...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002716-27 Sponsor Protocol Number: ALN-CC5-005 Start Date*: 2019-06-11
    Sponsor Name:Alnylam Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy
    Medical condition: Immunoglobulin A nephropathy (IgAN)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005335-25 Sponsor Protocol Number: BV-NSCLC-002 Start Date*: 2015-06-08
    Sponsor Name:Bioven (Europe) Ltd.
    Full Title: A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage IV biomarker positive, wild type EGF-R, NSCLC patients eli...
    Medical condition: late stage (IIIb/IV) Non-small cell lung carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000951-14 Sponsor Protocol Number: RhoVac-002 Start Date*: 2019-08-26
    Sponsor Name:RhoVac ApS
    Full Title: A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed) FI (Completed) SE (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-003340-30 Sponsor Protocol Number: GM307 Start Date*: 2008-08-21
    Sponsor Name:Genta Incorporated
    Full Title: A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)
    Medical condition: Advanced Melanoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Ongoing) DE (Completed) CZ (Completed) ES (Ongoing) AT (Completed) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003160-27 Sponsor Protocol Number: Sobi.PEGCET-101 Start Date*: 2022-05-31
    Sponsor Name:Swedish Orphan Biovitrum AB
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)
    Medical condition: Patients with Cold Agglutinin Disease (CAD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NO (Prematurely Ended) HU (Prematurely Ended) AT (Completed) IT (Prematurely Ended) BG (Completed) ES (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002818-40 Sponsor Protocol Number: EHVA_T02/ANRS_VRI07 Start Date*: 2019-10-25
    Sponsor Name:Inserm-ANRS
    Full Title: A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection
    Medical condition: Human Immunodeficiency Virus (HIV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003693-31 Sponsor Protocol Number: C3671013 Start Date*: 2021-09-30
    Sponsor Name:Pfizer Inc., 66 Hudson Boulevard East New York, NY 10001
    Full Title: A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
    Medical condition: Prevention of RSV-associated lower respiratory tract illness in adults 60 years of age and older by active immunization
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005544-17 Sponsor Protocol Number: EMR 200038-010 Start Date*: 2009-08-20
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy...
    Medical condition: post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Completed) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) SK (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017282-35 Sponsor Protocol Number: 113617 Start Date*: 2010-07-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects
    Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000602-10 Sponsor Protocol Number: SNT-III-012 Start Date*: 2016-11-17
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Ste...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) IE (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006710-36 Sponsor Protocol Number: V116-007 Start Date*: 2022-08-29
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator- Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035644 Pneumococcal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023124-24 Sponsor Protocol Number: LUMCCHIP Start Date*: 2011-03-02
    Sponsor Name:Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum
    Full Title: Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. ...
    Medical condition: Recurrent platinum resistant, p53 positive ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000552-33 Sponsor Protocol Number: LUMC_2012 Start Date*: 2012-11-27
    Sponsor Name:Leiden University Medical Center
    Full Title: Adoptive T cell therapy plus vaccination in metastatic melanoma patients
    Medical condition: Metastasized melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019438-28 Sponsor Protocol Number: 2010-019438-28 Start Date*: 2010-05-17
    Sponsor Name:Mälarsjukhuset Eskilstuna
    Full Title: Vaccination against TBE in patients who use immunosuppressive drugs
    Medical condition: TBE vaccin in patients using immunosuppressive drugs
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046859 Vaccination LLT
    12.1 10037153 Psoriasis LLT
    12.1 10039073 Rheumatoid arthritis LLT
    12.1 10054980 Immunosuppressant drug therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001712-35 Sponsor Protocol Number: N/2013/67 Start Date*: 2015-09-01
    Sponsor Name:Centre Hospitalier Régional Universitaire de Besançon
    Full Title: ANTICANCER THERAPEUTIC VACCINATION USING TELOMERASE-DERIVED UNIVERSAL CANCER PEPTIDES IN METASTATIC NON SMALL CELL LUNG CANCER
    Medical condition: lung cancer non-small cell
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002411-26 Sponsor Protocol Number: UV1/hTERT-2012-P Start Date*: 2013-03-18
    Sponsor Name:Oslo University Hospital
    Full Title: A PHASE I/IIA STUDY OF UV1 VACCINATION IN PATIENTS WITH HORMONE-SENSITIVE METASTATIC PROSTATE CANCER.
    Medical condition: Patients with advanced oligometastatic prostate cancer (PCa) without lung and/or liver metastases who are eligible to Complete Androgen Blockade therapy (GnRH-agonist combined with anti-androgen).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 08:50:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA